On 3 February 2025, Equilab International, Indonesia's largest Contract Research Organization (CRO), proudly announces the signing of a Memorandum of Understanding (MoU) with RSUD Dr. Soetomo, one of Indonesia's largest national referral hospitals. The MoU signing ceremony was attended by Prof. dr. Cita Rosita Sigit Prakoeswa, Director of RSUD Dr. Soetomo and Ronal Simanjuntak, President Director of Equilab International, along with hospital executives, physicians, clinicians, and clinical research unit representatives, as well as Equilab's executive team.
This landmark partnership marks a significant step forward for Equilab International in enhancing oncology clinical trial capacity in Indonesia. The collaboration aims to accelerate the development of innovative cancer treatments and improve patient outcomes in the region. By combining Equilab International's expertise in clinical trial management with RSUD Dr. Soetomo's renowned oncology program, the partnership will facilitate the conduct of high-quality oncology clinical trials in Indonesia, providing patients with access to novel and potentially life-saving treatments.
Ronal Simanjuntak, President Director of Equilab International expressed his vision about the future of Indonesian oncology trial. “We are excited about this partnership and believe it will pave the way for a significant increase in oncology trials in Indonesia. Currently we start from prostate cancer drug this February and more studies in upcoming months. We envision a future where Indonesia becomes a hub for innovative cancer research, and we're proud to be playing a role in making that vision a reality," said him.
Prof. dr. Cita Rosita Sigit Prakoeswa, Director of RSUD Dr. Soetomo, also expressed her hope to accelerate cancer research and improve cancer patient well-being in Indonesia. "I am hopeful that this partnership will bring positive impact to cancer patients in Indonesia. We also hope that cancer patients in Indonesia have access to more innovative, effective, and accessible cancer treatments through clinical trials," said Prof. Cita.